Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Mar 5;9(3):e70095.
doi: 10.1002/hem3.70095. eCollection 2025 Mar.

TIF Guidelines for the Management of Transfusion-Dependent β-Thalassemia

Khaled M Musallam  1   2   3 , Maria Domenica Cappellini  4 , John B Porter  5 , Dimitrios Farmakis  6 , Androulla Eleftheriou  7 , Michael Angastiniotis  7 , Ali T Taher  8
Affiliations
Editorial

TIF Guidelines for the Management of Transfusion-Dependent β-Thalassemia

Khaled M Musallam et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

K. M. M. reports consultancy fees from Novartis, Bristol Myers Squibb (Celgene Corp), Agios Pharmaceuticals, CRISPR Therapeutics, Vifor Pharma, Novo Nordisk, and Pharmacosmos; and research funding from Agios Pharmaceuticals and Pharmacosmos. M. D. C. reports consultancy fees from Novartis, Bristol Myers Squibb (Celgene Corp), Vifor Pharma, and Vertex Pharmaceuticals; and research funding from Novartis, Bristol Myers Squibb (Celgene Corp), La Jolla Pharmaceutical Company, Roche, Protagonist Therapeutics, and CRISPR Therapeutics. J. B. P. reports honoraria from Agios Pharmaceuticals, bluebird bio, Celgene (Bristol Myers Squibb), La Jolla Pharmaceuticals, Protagonism, Silence Therapeutics, and Vifor; and is a consultant for Agios Pharmaceuticals, bluebird bio, and Celgene (Bristol Myers Squibb). D. F. reports speaker honoraria, consultation fees, and/or grants from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Leo, Myocardial Solutions, and Roche. A. T. T. reports consultancy fees from Novo Nordisk, Bristol Myers Squibb (Celgene Corp), Agios Pharmaceuticals, Pharmacosmos, and Roche; and research funding from Novo Nordisk, Bristol Myers Squibb (Celgene Corp), Agios Pharmaceuticals, Pharmacosmos, and Roche. All competing interests are outside the present work. The remaining authors have no conflicts of interest to disclose.

References

    1. Forni GL, Gianesin B, Musallam KM, et al. Overall and complication‐free survival in a large cohort of patients with β‐thalassemia major followed over 50 years. Am J Hematol. 2023;98(3):381‐387. - PubMed
    1. Eleftheriou A, Angastiniotis M. Global Thalassaemia Review 2023. Thalassaemia International Federation; 2023.
    1. Kattamis A, Forni GL, Aydinok Y, Viprakasit V. Changing patterns in the epidemiology of β‐thalassemia. Eur J Haematol. 2020;105(6):692‐703. - PMC - PubMed
    1. Pinto VM, Poggi M, Russo R, Giusti A, Forni GL. Management of the aging beta‐thalassemia transfusion‐dependent population ‐ The Italian experience. Blood Rev. 2019;38:100594. - PubMed
    1. Farmakis D, Giakoumis A, Angastiniotis M, Eleftheriou A. The changing epidemiology of the ageing thalassaemia populations: a position statement of the Thalassaemia International Federation. Eur J Haematol. 2020;105(1):16‐23. - PubMed

Publication types

LinkOut - more resources